Nisa Investment Advisors LLC Sells 23,279 Shares of Moderna, Inc. $MRNA

Nisa Investment Advisors LLC cut its position in Moderna, Inc. (NASDAQ:MRNA) by 68.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,829 shares of the company’s stock after selling 23,279 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Moderna were worth $299,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. S Bank Fund Management Ltd bought a new stake in Moderna in the 1st quarter valued at about $25,000. TD Private Client Wealth LLC raised its stake in Moderna by 348.8% in the 2nd quarter. TD Private Client Wealth LLC now owns 956 shares of the company’s stock valued at $26,000 after acquiring an additional 743 shares during the period. SVB Wealth LLC bought a new stake in shares of Moderna in the first quarter valued at approximately $28,000. Whittier Trust Co. bought a new stake in shares of Moderna in the second quarter valued at approximately $28,000. Finally, CX Institutional raised its position in shares of Moderna by 1,129.8% in the second quarter. CX Institutional now owns 1,033 shares of the company’s stock valued at $29,000 after purchasing an additional 949 shares during the period. 75.33% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Cowen assumed coverage on shares of Moderna in a report on Sunday, July 13th. They set a “hold” rating on the stock. Morgan Stanley boosted their price objective on Moderna from $31.00 to $32.00 and gave the company an “equal weight” rating in a research note on Friday, October 10th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Moderna in a research note on Wednesday, October 8th. Citigroup decreased their price target on Moderna from $30.00 to $28.00 and set a “neutral” rating on the stock in a research report on Thursday, October 23rd. Finally, UBS Group decreased their price target on Moderna from $70.00 to $40.00 and set a “buy” rating on the stock in a research report on Thursday, October 23rd. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, twelve have issued a Hold rating and five have given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $36.86.

Moderna Stock Down 8.3%

Shares of NASDAQ MRNA opened at $24.91 on Tuesday. The stock’s 50-day simple moving average is $25.85 and its two-hundred day simple moving average is $27.18. The firm has a market capitalization of $9.73 billion, a P/E ratio of -3.31 and a beta of 2.02. Moderna, Inc. has a twelve month low of $23.15 and a twelve month high of $56.69.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Friday, August 1st. The company reported ($2.13) earnings per share for the quarter, topping the consensus estimate of ($2.99) by $0.86. The company had revenue of $142.00 million for the quarter, compared to analysts’ expectations of $116.26 million. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. Moderna’s revenue for the quarter was down 41.1% compared to the same quarter last year. During the same period in the prior year, the business earned ($3.33) earnings per share. As a group, research analysts anticipate that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.